Physician profile
William L Cooper
NPI 1477512663
$1,600.75
in general payments reported to CMS, 2019-2025
25 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $75.26 · 2021: $193 · 2022: $270 · 2023: $296 · 2024: $151 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $301.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $213.23 | 2019-2025 | |
| Astellas Pharma US INC | $155.14 | 2019-2024 | Veozah |
| Novo Nordisk INC | $145.38 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $118.25 | 2019-2025 | Evenity |
| Abbvie INC. | $114.87 | 2019-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $81.26 | 2019-2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $79.99 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $70.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.30 | 2019-2022 | |
| Lilly USA, LLC | $67.54 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Leo Pharma INC. | $26.66 | 2025 | Adbry |
| Incyte Corporation | $23.24 | 2022 | |
| Sumitomo Pharma America, INC. | $22.92 | 2023 | Gemtesa |
| Medtronic Vascular, INC. | $22.24 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $19.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.11 | 2024 | Ofev |
| Sanofi Pasteur INC. | $14.40 | 2023 | |
| Abbott Laboratories | $14.39 | 2021 | |
| Insmed, INC. | $14.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $6.84 | 2025 | Voquezna |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.